Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG
- PMID: 19075247
- PMCID: PMC2634951
- DOI: 10.1073/pnas.0806244105
Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG
Abstract
Respiratory syncytial virus (RSV) is one of the leading causes of childhood hospitalization and a major health burden worldwide. Unfortunately, because of an inefficient immunological memory, RSV infection provides limited immune protection against reinfection. Furthermore, RSV can induce an inadequate Th2-type immune response that causes severe respiratory tract inflammation and obstruction. It is thought that effective RSV clearance requires the induction of balanced Th1-type immunity, involving the activation of IFN-gamma-secreting cytotoxic T cells. A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which has been used in newborns for decades in several countries as a tuberculosis vaccine. Here, we show that immunization with recombinant BCG strains expressing RSV antigens promotes protective Th1-type immunity against RSV in mice. Activation of RSV-specific T cells producing IFN-gamma and IL-2 was efficiently obtained after immunization with recombinant BCG. This type of T cell immunity was protective against RSV challenge and caused a significant reduction of inflammatory cell infiltration in the airways. Furthermore, mice immunized with recombinant BCG showed no weight loss and reduced lung viral loads. These data strongly support recombinant BCG as an efficient vaccine against RSV because of its capacity to promote protective Th1 immunity.
Conflict of interest statement
Conflict of interest: A patent application on this work has been filed.
Figures






Similar articles
-
Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.J Immunol. 2010 Dec 15;185(12):7633-45. doi: 10.4049/jimmunol.0903452. Epub 2010 Nov 17. J Immunol. 2010. PMID: 21084664
-
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5. Vaccine. 2017. PMID: 28065474
-
Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells.J Virol. 2023 Mar 30;97(3):e0176422. doi: 10.1128/jvi.01764-22. Epub 2023 Feb 13. J Virol. 2023. PMID: 36779760 Free PMC article.
-
Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.Front Immunol. 2018 Mar 2;9:323. doi: 10.3389/fimmu.2018.00323. eCollection 2018. Front Immunol. 2018. PMID: 29552008 Free PMC article. Review.
-
Mucosal vaccines against respiratory syncytial virus.Curr Opin Virol. 2014 Jun;6:78-84. doi: 10.1016/j.coviro.2014.03.009. Epub 2014 Apr 29. Curr Opin Virol. 2014. PMID: 24794644 Free PMC article. Review.
Cited by
-
All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?Vaccines (Basel). 2024 Jan 18;12(1):97. doi: 10.3390/vaccines12010097. Vaccines (Basel). 2024. PMID: 38250910 Free PMC article. Review.
-
BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus.Vaccines (Basel). 2022 May 4;10(5):721. doi: 10.3390/vaccines10050721. Vaccines (Basel). 2022. PMID: 35632475 Free PMC article.
-
Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.Pathogens. 2023 Oct 19;12(10):1259. doi: 10.3390/pathogens12101259. Pathogens. 2023. PMID: 37887775 Free PMC article. Review.
-
Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection.Virology. 2009 Aug 1;390(2):151-6. doi: 10.1016/j.virol.2009.05.004. Epub 2009 Jun 2. Virology. 2009. PMID: 19493556 Free PMC article.
-
Recombinant BCG Expressing IL-12 as A Novel Immunomodulatory Strategy for Allergic Asthma: Opportunities and Challenges.Clin Rev Allergy Immunol. 2025 Jun 7;68(1):54. doi: 10.1007/s12016-025-09066-x. Clin Rev Allergy Immunol. 2025. PMID: 40483388 Review.
References
-
- Hacking D, Hull J. Respiratory syncytial virus-viral biology and the host response. J Infect. 2002;45:18–24. - PubMed
-
- Mejias A, Chavez-Bueno S, Jafri HS, Ramilo O. Respiratory syncytial virus infections: Old challenges and new opportunities. Pediatr Infect Dis J. 2005;24:S189–S196. - PubMed
-
- Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med. 2002;8:54–60. - PubMed
-
- Braciale TJ. Respiratory syncytial virus and T cells: Interplay between the virus and the host adaptive immune system. Proc Am Thorac Soc. 2005;2:141–146. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical